Name of the Procedure:

Injection, atezolizumab, 10 mg (HCPCS Code: J9022)

Summary

Atezolizumab is a medication used to treat certain types of cancer by boosting the body's immune system to fight cancer cells. This procedure involves injecting 10 mg of atezolizumab directly into the patient's bloodstream.

Purpose

Atezolizumab is used to treat cancers such as non-small cell lung cancer and urothelial carcinoma. The goal is to slow down or stop the growth of cancer cells, ultimately aiming to extend the patient's life and improve quality of life.

Indications

Patients with conditions like non-small cell lung cancer, urothelial carcinoma, and other cancers determined by a healthcare provider to be responsive to atezolizumab. Candidates typically have undergone previous treatments that were either ineffective or where additional treatments are sought.

Preparation

• Patients may need to fast for a few hours before the injection.
• Adjustments to current medications may be necessary.
• Pre-procedure tests like blood work or imaging studies might be required to ensure the patient's suitability for atezolizumab.

Procedure Description

1. The patient will be positioned comfortably, typically in a seated or reclined position.
2. An intravenous (IV) line will be established, usually in the arm.
3. Atezolizumab will be prepared and administered through the IV line over a set period, generally taking 30 to 60 minutes.
4. Medical staff will monitor the patient for any immediate reactions during and after the infusion.

Duration

The injection procedure itself typically takes around 30 to 60 minutes. Preparation and post-procedure monitoring may extend the visit to about 2-3 hours.

Setting

This procedure is performed in a variety of settings including hospitals, outpatient clinics, and specialized infusion centers.

Personnel

• Oncology-trained nurses or infusion specialists to administer the medication,
• Medical oncologists to oversee the treatment plan,
• Possibly a pharmacist to prepare the medication.

Risks and Complications

• Common: Fatigue, nausea, decreased appetite, and infusion-related reactions.
• Rare: Severe immune-related reactions affecting organs such as lungs (pneumonitis), liver (hepatitis), and other less common complications.
• Management involves symptomatic treatments and, if necessary, discontinuing atezolizumab.

Benefits

• Potential to slow the progression of cancer.
• Possible improvement in quality of life.
• The benefits may become noticeable after several treatments, contingent on individual responses.

Recovery

• Post-injection monitoring for a short period to observe any acute reactions.
• Patients can usually return to normal activities within a day.
• Regular follow-up appointments are necessary to monitor the response to the treatment and manage side effects.

Alternatives

• Other immunotherapy drugs,
• Chemotherapy,
• Radiation therapy,
• Surgical options depending on the type and stage of cancer.
  • Alternatives vary in terms of effectiveness, side effects, and suitable candidates.

Patient Experience

• During the procedure: Some discomfort from the IV insertion, but generally minimal pain.
• After the procedure: Possible mild side effects such as fatigue and nausea; pain management strategies include over-the-counter medications and resting.
• Continuous communication with healthcare providers will help manage and mitigate any adverse experiences.